Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | APEX1 | P27695 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11801332 | 0.83 | KDM4E (0.42) | KDM4ELMNAALDH1A1POLBKMT2A | |
| SCHEMBL13956720 | 0.80 | KDM4E (0.36) | KDM4ELMNAALDH1A1POLBAPEX1 | |
| SCHEMBL14420618 | 0.80 | ALDH1A1 (0.39) | KDM4ELMNAALDH1A1POLBAPEX1 | |
| SCHEMBL7641822 | 0.79 | ALDH1A1 (0.36) | KDM4ELMNAALDH1A1POLBAPEX1 | |
| SCHEMBL16728405 | 0.79 | ALDH1A1 (0.39) | ALDH1A1POLBAPEX1TDP1KMT2A | |
| SCHEMBL19387893 | 0.79 | ALDH1A1 (0.39) | ALDH1A1POLBAPEX1TDP1KMT2A | |
| SCHEMBL29928799 | 0.79 | ALDH1A1 (0.39) | ALDH1A1POLBAPEX1TDP1KMT2A | |
| SCHEMBL20548051 | 0.78 | POLB (0.48) | KDM4ELMNAPOLBAPEX1TDP1 | |
| SCHEMBL22361971 | 0.78 | POLB (0.48) | KDM4ELMNAPOLBAPEX1TDP1 | |
| SCHEMBL6811019 | 0.78 | KDM4E (0.42) | KDM4ELMNAALDH1A1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6753128-B2 | BLOCKING ACID GENERATION DURING PHOTOLITHOGRAPHY | HYNIX SEMICONDUCTOR INC. (KR) | 2004-06-22 | — | — | US | disclosed |
| US-20030082481-A1 | Photoresist additive for preventing acid migration and photoresist composition comprising the same | HYNIX SEMICONDUCTOR INC. (KR) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082481-A1 | Photoresist additive for preventing acid migration and photoresist composition comprising the same | RARG, ELMO1, COL2A1 | KDM4E 4226/4885LMNA 567/4885ALDH1A1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.